Prognostic significance of diagnosis-to-treatment interval in acute- and lymphoma-type adult T-cell leukemia/lymphoma
International Journal of Hematology · 04.11.2026
DOI: 10.1007/s12185-026-04302-2 ↗Kurz gefasst
Fachartikel in der Zeitschrift International Journal of Hematology, online erschienen am 04.11.2026. Verfasst von Kikuaki Yoshida und 10 weiteren Autor:innen. Beteiligte Einrichtung: Department of Hematology/Oncology, Wakayama Medical University, Kimiidera 811-1, Wakayama, 641-8509, Japan. Die Arbeit nennt 19 Literaturangaben.
Abstract (Originalsprache)
Acute- and lymphoma-type adult T-cell leukemia/lymphoma (ATL) is clinically aggressive, but the prognostic significance of the diagnosis-to-treatment interval (DTI) is unclear. We retrospectively analyzed 73 patients with newly diagnosed acute- or lymphoma-type ATL who received systemic chemotherapy between 2003 and 2025. DTI was defined as the interval from diagnosis to chemotherapy initiation, with the diagnosis date defined as the biopsy date rather than the date of pathological confirmation, or, in patients without a biopsy, the date of confirmation by peripheral blood testing. A short DTI was defined as ≤7 days. The median DTI was 11 days. Peripheral blood involvement and acute-type ATL were more frequent in the short DTI group. A short DTI was associated with inferior overall survival (OS) (HR, 1.75; 95% CI, 1.04–2.92; p = 0.034), but not progression-free or post-progression survival. After adjustment for the simplified ATL prognostic index, a short DTI remained associated with inferior OS (adjusted HR, 1.75; 95% CI, 1.04–2.93; p = 0.035). DTI may provide prognostic information complementary to conventional baseline factors in ATL; however, it reflects healthcare- and disease-related factors, residual confounding cannot be excluded, and validation in larger cohorts is required.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Hematology/Oncology, Wakayama Medical University, Kimiidera 811-1, Wakayama, 641-8509, Japan.
- Department of Hematology, Kinan Hospital, Wakayama, Japan.
- Department of Hematology/Oncology, Wakayama Medical University, Kimiidera 811-1, Wakayama, 641-8509, Japan. h-hosoi@wakayama-med.ac.jp.
- Department of Transfusion Medicine, Wakayama Medical University Hospital, Wakayama, Japan. h-hosoi@wakayama-med.ac.jp.
- Clinical Study Support Center, Wakayama Medical University, Wakayama, Japan.
- Community Medical Support Center, Wakayama Medical University, Wakayama, Japan.
Zitieren
APA
Yoshida, K., Hosoi, H., Amano, Y., Okamura, T., Wan, K., Tabata, S., Kosako, H., Tanaka, K., Murata, S., Mushino, T., & Sonoki, T. (2026). Prognostic significance of diagnosis-to-treatment interval in acute- and lymphoma-type adult T-cell leukemia/lymphoma. International Journal of Hematology. https://doi.org/10.1007/s12185-026-04302-2
Vancouver
Yoshida K, Hosoi H, Amano Y, Okamura T, Wan K, Tabata S, et al. Prognostic significance of diagnosis-to-treatment interval in acute- and lymphoma-type adult T-cell leukemia/lymphoma. International Journal of Hematology. 2026. doi:10.1007/s12185-026-04302-2
BibTeX
@article{Yoshida2026,
author = {Yoshida, Kikuaki and Hosoi, Hiroki and Amano, Yuto and Okamura, Tadashi and Wan, Ke and Tabata, Shotaro and Kosako, Hideki and Tanaka, Ken and Murata, Shogo and Mushino, Toshiki and Sonoki, Takashi},
title = {Prognostic significance of diagnosis-to-treatment interval in acute- and lymphoma-type adult T-cell leukemia/lymphoma},
journal = {International Journal of Hematology},
year = {2026},
doi = {10.1007/s12185-026-04302-2}
}
EUVIMED